Bli medlem
Bli medlem

Du är här

2022-08-18

Redeye: AroCell - Good cost control, somewhat lower sales

Redeye returns with a more detailed take on the Q2 report and notes lower costs than expected and anticipate a continuous upswing of TUBEX sales while lowering FY 2022E sales somewhat. We reiterate our fair value range.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments


AroCell - Good cost control, somewhat lower sales

Författare MFN